Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
44 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Nymox Pharmaceutical Corporation - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Nymox Pharmaceutical Corporation - Product Pipeline Review - 2014', provides an overview of the Nymox Pharmaceutical Corporation's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Nymox Pharmaceutical Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Nymox Pharmaceutical Corporation including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Nymox Pharmaceutical Corporation's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Nymox Pharmaceutical Corporation's pipeline products Reasons to buy - Evaluate Nymox Pharmaceutical Corporation's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Nymox Pharmaceutical Corporation in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Nymox Pharmaceutical Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Nymox Pharmaceutical Corporation and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Nymox Pharmaceutical Corporation - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Nymox Pharmaceutical Corporation and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Nymox Pharmaceutical Corporation Snapshot 5 Nymox Pharmaceutical Corporation Overview 5 Key Information 5 Key Facts 5 Nymox Pharmaceutical Corporation - Research and Development Overview 6 Key Therapeutic Areas 6 Nymox Pharmaceutical Corporation - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Nymox Pharmaceutical Corporation - Pipeline Products Glance 11 Nymox Pharmaceutical Corporation - Late Stage Pipeline Products 11 Phase III Products/Combination Treatment Modalities 11 Nymox Pharmaceutical Corporation - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Nymox Pharmaceutical Corporation - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Discovery Products/Combination Treatment Modalities 14 Nymox Pharmaceutical Corporation - Drug Profiles 15 NX-1207 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 Drugs for Oncology 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 NXB-4221 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 NXD-1191 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 NXD-3109 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 NXD-5150 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 NXD-9062 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 NXB-5886 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 NXC-4720 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 NXT-1021 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Nymox Pharmaceutical Corporation - Pipeline Analysis 26 Nymox Pharmaceutical Corporation - Pipeline Products by Route of Administration 26 Nymox Pharmaceutical Corporation - Pipeline Products by Molecule Type 27 Nymox Pharmaceutical Corporation - Recent Pipeline Updates 28 Nymox Pharmaceutical Corporation - Dormant Projects 39 Nymox Pharmaceutical Corporation - Company Statement 40 Nymox Pharmaceutical Corporation - Locations And Subsidiaries 42 Head Office 42 Other Locations & Subsidiaries 42 Appendix 43 Methodology 43 Coverage 43 Secondary Research 43 Primary Research 43 Expert Panel Validation 43 Contact Us 44 Disclaimer 44
List of Tables Nymox Pharmaceutical Corporation, Key Information 5 Nymox Pharmaceutical Corporation, Key Facts 5 Nymox Pharmaceutical Corporation - Pipeline by Indication, 2014 7 Nymox Pharmaceutical Corporation - Pipeline by Stage of Development, 2014 9 Nymox Pharmaceutical Corporation - Monotherapy Products in Pipeline, 2014 10 Nymox Pharmaceutical Corporation - Phase III, 2014 11 Nymox Pharmaceutical Corporation - Phase II, 2014 12 Nymox Pharmaceutical Corporation - Preclinical, 2014 13 Nymox Pharmaceutical Corporation - Discovery, 2014 14 Nymox Pharmaceutical Corporation - Pipeline by Route of Administration, 2014 26 Nymox Pharmaceutical Corporation - Pipeline by Molecule Type, 2014 27 Nymox Pharmaceutical Corporation - Recent Pipeline Updates, 2014 28 Nymox Pharmaceutical Corporation - Dormant Developmental Projects,2014 39 Nymox Pharmaceutical Corporation, Subsidiaries 42
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.